NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer. (28th November 2022)
- Record Type:
- Journal Article
- Title:
- NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer. (28th November 2022)
- Main Title:
- NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer
- Authors:
- Magallanes-Garza, Gerardo I.
Santuario-Facio, Sandra K.
Lira-Albarrán, Saúl
Varela-Varela, Arlina F.
Cardona-Huerta, Servando
Ruiz-Flores, Pablo
Haro-Santa-Cruz, Jorge
Perez-Paramo, Yadira X.
Gomez-Macias, Gabriela Sofia
Davila-Gonzalez, Daniel
Valero-Gomez, Javier
Borrego-Soto, Gissela
Rojas-Martinez, Augusto
Ortiz-Lopez, Rocio - Other Names:
- Li Tian Academic Editor.
- Abstract:
- Abstract : Purpose . To evaluate whether changes in genomic expression that occur beginning with breast cancer (BC) diagnosis and through to tumor resection after neoadjuvant chemotherapy (NCT) reveal biomarkers that can help predict therapeutic response and survival. Materials and Methods . We determined gene expression profiles based on microarrays in tumor samples from 39 BC patients who showed pathologic complete response (pCR) or therapeutic failure (non-pCR) after NCT (cyclophosphamide-doxorubicin/epirubicin). Based on unsupervised clustering of gene expression, together with functional enrichment analyses of differentially expressed genes, we selected NUSAP1, PCLAF, MME, and DST . We evaluated the NCT response and the expression of these four genes in BC histologic subtypes. In addition, we study the presence of tumor-infiltrating lymphocytes. Finally, we analyze the correlation between NUSAP1 and PCLAF against disease-free survival (DFS) and overall survival (OS). Results . A signature of 43 differentially expressed genes discriminated pCR from non-pCR patients (|fold change >2|, false discovery rate <0.05) only in biopsies taken after surgery. Patients achieving pCR showed downregulation of NUSAP1 and PCLAF in tumor tissues and increased DFS and OS, while overexpression of these genes correlated with poor therapeutic response and OS. These genes are involved in the regulation of mitotic division. Conclusions . The downregulation of NUSAP1 and PCLAF after NCT isAbstract : Purpose . To evaluate whether changes in genomic expression that occur beginning with breast cancer (BC) diagnosis and through to tumor resection after neoadjuvant chemotherapy (NCT) reveal biomarkers that can help predict therapeutic response and survival. Materials and Methods . We determined gene expression profiles based on microarrays in tumor samples from 39 BC patients who showed pathologic complete response (pCR) or therapeutic failure (non-pCR) after NCT (cyclophosphamide-doxorubicin/epirubicin). Based on unsupervised clustering of gene expression, together with functional enrichment analyses of differentially expressed genes, we selected NUSAP1, PCLAF, MME, and DST . We evaluated the NCT response and the expression of these four genes in BC histologic subtypes. In addition, we study the presence of tumor-infiltrating lymphocytes. Finally, we analyze the correlation between NUSAP1 and PCLAF against disease-free survival (DFS) and overall survival (OS). Results . A signature of 43 differentially expressed genes discriminated pCR from non-pCR patients (|fold change >2|, false discovery rate <0.05) only in biopsies taken after surgery. Patients achieving pCR showed downregulation of NUSAP1 and PCLAF in tumor tissues and increased DFS and OS, while overexpression of these genes correlated with poor therapeutic response and OS. These genes are involved in the regulation of mitotic division. Conclusions . The downregulation of NUSAP1 and PCLAF after NCT is associated with the tumor response to chemotherapy and patient survival. … (more)
- Is Part Of:
- Journal of oncology. Volume 2022(2022)
- Journal:
- Journal of oncology
- Issue:
- Volume 2022(2022)
- Issue Display:
- Volume 2022, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 2022
- Issue:
- 2022
- Issue Sort Value:
- 2022-2022-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-11-28
- Subjects:
- Oncology -- Research -- Periodicals
Tumors -- Periodicals
Neoplasms
Oncology -- Research
Tumors
Periodicals
Periodicals
616.994 - Journal URLs:
- https://www.hindawi.com/journals/jo/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=859&action=archive ↗ - DOI:
- 10.1155/2022/6001947 ↗
- Languages:
- English
- ISSNs:
- 1687-8450
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 24738.xml